Patents by Inventor Likai YANG

Likai YANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11931467
    Abstract: Disclosed herein is an albumin pharmaceutical composition, comprising albumin and at least one amino acid having a relative molecular mass of 145-175. Clinically, the albumin pharmaceutical composition can effectively reduce undesirable responses, such as rash, urticaria, anaphylaxis and possible immune responses in the human body caused by albumin polymers and dimers, thereby further ensuring the safety in clinical medication.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: March 19, 2024
    Assignee: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
    Inventors: Zhengxing Su, Likai Yang, Dong Zhao, Yujun Wang, Fengying Shan, Kexing Wang, Lichun Wang, Jingyi Wang
  • Publication number: 20230219990
    Abstract: Disclosed is a method for preparing a C-nucleoside compound represented by Formula (III) or salt thereof. The present method has a high reaction yield, is simple to operate, uses a single metal reagent, has stable reaction temperature conditions, does not require frequent changes to the reaction system during the operation process, is suitable for scale-up synthesis, is suitable for large-scale production of Remdesivir, and has low costs.
    Type: Application
    Filed: July 15, 2021
    Publication date: July 13, 2023
    Inventors: Yong Qin, Wu Zhong, Fei Xue, Xiaoyu Liu, Yu Wang, Xiaohan Zhou, Bo Liu, Ke Wang, Likai Yang, Ruijie Zhou, Yaxin Xiao, Fanglin Xue, Minjie Zhang, Hao Song, Zhibing Zheng, Song Li
  • Patent number: 11395812
    Abstract: The present invention relates to a docetaxel albumin nanoparticle pharmaceutical composition, a preparation method therefor, and a use thereof for manufacturing drugs for treating cancer. The pharmaceutical composition comprises docetaxel, albumin and amino acid(s), wherein the weight ratio between albumin and docetaxel is no more than 50, preferably is 20:1 to 1:1, and the weight ratio between amino acid(s) and docetaxel is not less than 0.5, preferably is 1:1 to 20:1.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 26, 2022
    Assignee: SICHUAN KELUN PHARMACEUTICAL RESEARCH INSTITUTE CO. LTD.
    Inventors: Zhengxing Su, Likai Yang, Dong Zhao, Jing Zhou, Fengying Shan, Lichun Wang, Jingyi Wang
  • Publication number: 20220000792
    Abstract: Disclosed herein is an albumin pharmaceutical composition, comprising albumin and at least one amino acid having a relative molecular mass of 145-175.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 6, 2022
    Applicant: SICHUAN KELUN PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD.
    Inventors: Zhengxing SU, Likai YANG, Dong ZHAO, Yujun WANG, Fengying SHAN, Kexing WANG, Lichun WANG, Jingyi WANG
  • Patent number: 11154511
    Abstract: Disclosed herein is an albumin pharmaceutical composition, comprising albumin and at least one amino acid having a relative molecular mass of 145-175. Clinically, the albumin pharmaceutical composition can effectively reduce undesirable responses, such as rash, urticaria, anaphylaxis and possible immune responses in the human body caused by albumin polymers and dimers, thereby further ensuring the safety in clinical medication.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: October 26, 2021
    Assignee: SICHUAN KELUN PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD.
    Inventors: Zhengxing Su, Likai Yang, Dong Zhao, Yujun Wang, Fengying Shan, Kexing Wang, Lichun Wang, Jingyi Wang
  • Publication number: 20200108022
    Abstract: Disclosed herein is an albumin pharmaceutical composition, comprising albumin and at least one amino acid having a relative molecular mass of 145-175. Clinically, the albumin pharmaceutical composition can effectively reduce undesirable responses, such as rash, urticaria, anaphylaxis and possible immune responses in the human body caused by albumin polymers and dimers, thereby further ensuring the safety in clinical medication.
    Type: Application
    Filed: September 21, 2017
    Publication date: April 9, 2020
    Inventors: Zhengxing Su, Likai Yang, Dong Zhao, Yujun Wang, Fengying Shan, Kexing Wang, Lichun Wang, Jingyi Wang
  • Publication number: 20200038362
    Abstract: The present invention relates to a docetaxel albumin nanoparticle pharmaceutical composition, a preparation method therefor, and a use thereof for manufacturing drugs for treating cancer. The pharmaceutical composition comprises docetaxel, albumin and amino acid(s), wherein the weight ratio between albumin and docetaxel is no more than 50, preferably is 20:1 to 1:1, and the weight ratio between amino acid(s) and docetaxel is not less than 0.5, preferably is 1:1 to 20:1.
    Type: Application
    Filed: September 25, 2019
    Publication date: February 6, 2020
    Applicant: SICHUAN KELUN PHARMACEUTICAL RESEARCH INSTITUTE CO. LTD.
    Inventors: Zhengxing SU, Likai YANG, Dong ZHAO, Jing ZHOU, Fengying SHAN, Lichun WANG, Jingyi WANG
  • Patent number: 10493054
    Abstract: The present invention relates to a docetaxel albumin nanoparticle pharmaceutical composition, a preparation method therefor, and a use thereof for manufacturing drugs for treating cancer. The pharmaceutical composition comprises docetaxel, albumin and amino acid(s), wherein the weight ratio between albumin and docetaxel is no more than 50, preferably is 20:1 to 1:1, and the weight ratio between amino acid(s) and docetaxel is not less than 0.5, preferably is 1:1 to 20:1.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: December 3, 2019
    Assignee: SICHUAN KELUN PHARMACEUTICAL RESEARCH INSTITUTE CO. LTD.
    Inventors: Zhengxing Su, Likai Yang, Dong Zhao, Jing Zhou, Fengying Shan, Lichun Wang, Jingyi Wang
  • Publication number: 20180028486
    Abstract: The present invention relates to a docetaxel albumin nanoparticle pharmaceutical composition, a preparation method therefor, and a use thereof for manufacturing drugs for treating cancer. The pharmaceutical composition comprises docetaxel, albumin and amino acid(s), wherein the weight ratio between albumin and docetaxel is no more than 50, preferably is 20:1 to 1:1, and the weight ratio between amino acid(s) and docetaxel is not less than 0.5, preferably is 1:1 to 20:1.
    Type: Application
    Filed: March 28, 2016
    Publication date: February 1, 2018
    Applicant: SICHUAN KELUN PHARMACEUTICAL RESEARCH INSTITUTE CO. LTD.
    Inventors: Zhengxing SU, Likai YANG, Dong ZHAO, Jing ZHOU, Fengying SHAN, Lichun WANG, Jingyi WANG